{"id":7664,"date":"2025-11-06T15:55:00","date_gmt":"2025-11-06T15:55:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/board-proposal-for-share-issue-appendix-from-notice-of-extraordinary-general-meeting\/"},"modified":"2025-11-06T15:55:00","modified_gmt":"2025-11-06T15:55:00","slug":"board-proposal-for-share-issue-appendix-from-notice-of-extraordinary-general-meeting","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/board-proposal-for-share-issue-appendix-from-notice-of-extraordinary-general-meeting\/","title":{"rendered":"Board Proposal for Share Issue \u2013 Appendix from Notice of Extraordinary General Meeting"},"content":{"rendered":"
\n

Scandinavian Real Heart AB hereby publishes the Board\u2019s complete proposal for a share issue, which was previously attached to the notice of the Extraordinary General Meeting on 24 October 2025<\/strong><\/p>\n<\/div>\n

\n

The Board of Directors propose that the General Meeting resolves on issuance of new shares, with preferential rights for the shareholders in accordance with below.<\/strong>

<\/strong>Reasons for the Offering and Use of Proceeds<\/strong><\/p>\n

Scandinavian Real Heart AB is conducting the Rights Issue of approximately SEK 70 million to secure continued financing of the Company\u2019s development work on Realheart\u00ae TAH \u2013 a total artificial heart designed to mimic the structure and function of the human heart. The product is intended to become a permanent solution for patients suffering from severe heart failure. Previous study results support that Realheart TAH has strong potential to replace the human heart in the future.<\/p>\n

Of the approximately 22 million patients suffering from heart failure in the EU and the US, the Company estimates that a patient population of around 160,000 with advanced (NYHA Class IV) biventricular heart failure represents the target group for TAH treatment. Furthermore, this translates into an annual number of patients requiring TAH treatment of approximately 25,000, expected to increase in line with overall heart failure prevalence to around 35,000 by 2030. The average market price for a TAH is USD 220,000, corresponding to a market potential of USD 34 billion. The US and EU are the largest markets, with Germany being the largest European market and therefore of significant interest to the Company. A collaboration with a German hospital has been initiated in preparation for future clinical trials.<\/p>\n

In 2025, the Company deepened its collaboration with Sahlgrenska University Hospital in Gothenburg, where surgical methodology and processes have been further developed based on experience from previous animal studies. The studies are led by cardiac surgeon Professor G\u00f6ran Dellgren together with a clinical team with extensive experience in heart transplantation. The objective is first to optimize surgical methodology, then conduct survival studies to compile regulatory documentation, and finally apply to initiate clinical trials.<\/p>\n

During 2025, the Company also increased its focus on product development. The Company has produced several TAH units with improved quality and simplified manufacturing processes compared to previous versions. The Company will continue to develop production processes and product quality, both through internal initiatives and in close collaboration with carefully selected partners. As part of this work, a move to more suitable facilities will take place in 2026. The TAH units manufactured by the Company will continuously be used in endurance tests running for up to six months, as well as in animal studies and blood tests. Endurance tests of the membrane, the most critical component, have exceeded 18 months in ongoing tests. To enable the transition to clinical studies, further design improvements of the product are required, which must be validated through endurance tests, animal studies, and blood tests. This work has already begun and will continue during 2026. The company is not communicating any guidance or forecast regarding the anticipated date for the first-in-human implant. Several studies have been conducted with previous versions compared to the market-leading competitor, showing superior results in blood tests and patient simulator studies (cardiovascular simulator, so-called hybrid simulator).<\/p>\n

If fully subscribed, the net proceeds (after estimated transaction costs of approximately SEK 300,000) are intended to be allocated as follows:<\/p>\n

TAH Unit \u2013 60%<\/strong><\/p>\n